Last reviewed · How we verify

Valproic Acid and Depakote ER

Joliet Center for Clinical Research · FDA-approved active Small molecule Quality 2/100

Valproic Acid and Depakote ER, marketed by Joliet Center for Clinical Research, is a well-established treatment in its class. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential competition from generic entries post-patent expiry.

At a glance

Generic nameValproic Acid and Depakote ER
SponsorJoliet Center for Clinical Research
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: